Literature DB >> 22372429

Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab.

Sandra T A van Bijnen, Roos S van Rijn, Senada Koljenovic, Peter te Boekhorst, Theo de Witte, Petra Muus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22372429     DOI： 10.1111/j.1365-2141.2012.09073.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

Review 1.  Successful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era.

Authors:  Yasuyoshi Morita; Jun-ichi Nishimura; Takahiro Shimada; Hirokazu Tanaka; Kentaro Serizawa; Yasuhiro Taniguchi; Mitsuhiro Tsuritani; Yuzuru Kanakura; Itaru Matsumura
Journal:  Int J Hematol       Date:  2013-03-02       Impact factor: 2.490

2.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

3.  Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.

Authors:  Peter Hillmen; Petra Muus; Alexander Röth; Modupe O Elebute; Antonio M Risitano; Hubert Schrezenmeier; Jeffrey Szer; Paul Browne; Jaroslaw P Maciejewski; Jörg Schubert; Alvaro Urbano-Ispizua; Carlos de Castro; Gérard Socié; Robert A Brodsky
Journal:  Br J Haematol       Date:  2013-04-25       Impact factor: 6.998
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.